期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 352, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2020.577468
关键词
EAE; Thyromimetics; Oligodendrocytes; Myelin; Inflammation
资金
- National Multiple Sclerosis Society [RG 5199A4, RG-1607-25053, RG 5106A1/1]
- Race to Erase MS
- OHSU Laura Fund for Innovation in Multiple Sclerosis
- NIH [DK52798, P30 NS061800]
The study demonstrated that thyromimetics could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis, reduce clinical disease symptoms, and protect oligodendrocytes against cell death.
We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models. We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE). Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes. T3 and Sob also protected cultured oligodendrocytes against cell death. Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据